The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Merck Serono; Pierre Fabre; Roche/Genentech; Sanofi; Seagen; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; Gilead Sciences; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Nordic Bioscience; Pierre Fabre; Seagen; SERVIER; Takeda/Lundbeck; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation; Gercor
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Pfizer; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Genentech (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Lars Henrik Jensen
Research Funding - 2cureX (Inst); BMS (Inst); Incyte (Inst); MSD (Inst)
 
Jaafar Bennouna
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Daichii; Daichii; Ipsen; Janssen Oncology; MSD Oncology; Novartis; SERVIER
Consulting or Advisory Role - AMGEN; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; SERVIER
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
 
Guillermo Mendez
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Grupo Biotoscana; Merck; MSD; Pfizer; Roche; SERVIER
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Expert Testimony - Bristol-Myers Squibb; MSD
Travel, Accommodations, Expenses - Amgen; Grupo Biotoscana; Merck; Pfizer; SERVIER
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; BIOVEN; Bristol-Myers Squibb; Clovis Oncology; Five Prime Therapeutics; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Mylan; Novartis; Pfizer/EMD Serono; Regeneron; Roche; Sanofi/Regeneron; Tesaro; Tesaro
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; Ipsen; Lilly; MSD Oncology; Pierre Fabre; Roche/Genentech; SERVIER
Research Funding - MSD (Inst); Natera (Inst); Pierre Fabre (Inst); Servier (Inst)
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Maria Luisa Limon
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Genomedia (Inst); Molecular Health (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Jin Li
No Relationships to Disclose
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Jose Luis Manzano Mozo
No Relationships to Disclose
 
Giampaolo Tortora
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; SERVIER
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca (I); Bayer; BMS; Boehringer Ingelheim; Esteve; Gilead Sciences (I); Hutchmed; Ipsen; Lilly (I); Merck; Midatech Pharma; Mirati Therapeutics (I); MSD; Novartis; Pfizer (I); PharmaMar; Roche (I); Sanofi (I); Servier; Takeda (I)
Consulting or Advisory Role - HMP
Research Funding - BMS (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Advanced Accelerator Applications/Novartis; Esteve; Ipsen; Merck; MSD
 
Elvis Cela
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Yingsi Yang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences; Jazz Pharmaceuticals
 
Ming Lei
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Patents, Royalties, Other Intellectual Property - Inventor of pending BMS patents
 
Lixian Jin
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)